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Abstract
Polycystic ovary syndrome (PCOS) is of clinical and public health importance as it is very common, affecting up to one 
in five women of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, 
hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, 
adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of 
life). Polycystic ovary syndrome is a heterogeneous condition and, as such, clinical and research agendas are broad and 
involve many disciplines. The phenotype varies widely depending on life stage, genotype, ethnicity and environmental 
factors including lifestyle and bodyweight. Importantly, PCOS has unique interactions with the ever increasing obesity 
prevalence worldwide as obesity-induced insulin resistance significantly exacerbates all the features of PCOS. 
Furthermore, it has clinical implications across the lifespan and is relevant to related family members with an increased 
risk for metabolic conditions reported in first-degree relatives. Therapy should focus on both the short and long-term 
reproductive, metabolic and psychological features. Given the aetiological role of insulin resistance and the impact of 
obesity on both hyperinsulinaemia and hyperandrogenism, multidisciplinary lifestyle improvement aimed at 
normalising insulin resistance, improving androgen status and aiding weight management is recognised as a crucial 
initial treatment strategy. Modest weight loss of 5% to 10% of initial body weight has been demonstrated to improve 
many of the features of PCOS. Management should focus on support, education, addressing psychological factors and 
strongly emphasising healthy lifestyle with targeted medical therapy as required. Monitoring and management of 
long-term metabolic complications is also an important part of routine clinical care. Comprehensive evidence-based 
guidelines are needed to aid early diagnosis, appropriate investigation, regular screening and treatment of this 
common condition. Whilst reproductive features of PCOS are well recognised and are covered here, this review focuses 
primarily on the less appreciated cardiometabolic and psychological features of PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is a frustrating expe-
rience for women, often complex for managing clinicians
and is a scientific challenge for researchers. As research
in PCOS is rapidly advancing, it is vital that research evi-
dence is translated to knowledge and action among
women, healthcare professionals and policy makers.
PCOS is the most common endocrine abnormality in
reproductive-age women. The prevalence of PCOS is tra-
ditionally estimated at 4% to 8% from studies performed
in Greece, Spain and the USA [1-4]. The prevalence of
PCOS has increased with the use of different diagnostic
criteria and has recently been shown to be 18% (17.8 ±
2.8%) in the first community-based prevalence study
based on current Rotterdam diagnostic criteria [5].
I m p o r t a n t l y ,  7 0 %  o f  w o m e n  i n  t h i s  r e c e n t  s t u d y  w e r e
undiagnosed [5]. While the upper limit of prevalence for
this study was imputed using estimates of polycystic ova-
ries (PCO) for women who had not had an ultrasound,
non-imputed prevalences were calculated as 11.9 ± 2.4%
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[5]. PCOS has also been noted to affect 28% of unselected
obese and 5% of lean women [5-8]. In 2006, based on US
data and traditionally lower prevalence estimates the
anticipated economic burden of PCOS in Australia was
AU$400 million (menstrual dysfunction 31%, infertility
12% and PCOS-associated diabetes 40% of total costs),
representing a major health and economic burden [8].
With regards to fertility, the estimated cost per birth in
overweight Australian women with PCOS is high [9].
Promisingly, lifestyle intervention comprising dietary,
exercise and behavioural therapy improves fertility and
reduces costs per birth significantly [9].
Aetiology: insulin resistance and hyperandrogenism
The exact pathophysiology of PCOS is complex and
remains largely unclear. Although a detailed discussion is
beyond the scope of this review, the underlying hormonal
imbalance created by a combination of increased andro-
gens and/or insulin underpin PCOS (Figure 1). Genetic
and environmental contributors to hormonal distur-
bances combine with other factors, including obesity,
ovarian dysfunction and hypothalamic pituitary abnor-
malities to contribute to the aetiology of PCOS [10,11].
However, greater understanding of pathophysiological
contributors in PCOS have been hampered by a lack of
ideal methods to assess either hyperandrogenism or insu-
lin resistance. Hyperandrogenism is a well established
contributor to PCOS aetiology, detected in around 60% to
80% of cases. Insulin resistance is a pathophysiological
contributor in around 50% to 80% of women with PCOS
[12], especially in those with more severe PCOS diag-
nosed on National Institutes of Health (NIH) criteria and
in women who are overweight. Conversely, lean women
[13] and women with milder PCOS diagnosed on newer
European Society for Human Reproduction (ESHRE)/
American Society of Reproductive Medicine (ASRM) cri-
teria [14] appear to have less severe hyperinsulinaemia
and insulin resistance. , Insulin resistance contributes to
metabolic features but also to reproductive features [15]
through augmenting androgen production and increasing
free androgens by reducing sex hormone binding globu-
lin (SHBG). In this setting of unclear aetiology and mech-
anisms of insulin resistance, further research is clearly
needed.
Impact of obesity on polycystic ovary syndrome
Obesity and excess weight are major chronic diseases in
Western world countries. Obesity increases hyperandro-
genism, hirsutism, infertility and pregnancy complica-
tions both independently and by exacerbating PCOS
[16,17]. In general populations, obesity and insulin resis-
tance further increase type 2 diabetes (DM2) and cardio-
vascular disease (CVD). Likewise, in PCOS obesity
worsens insulin resistance and exacerbates reproductive
and metabolic features [16,17]. Furthermore, women
w i t h  P C O S  h a v e  i n c r e a s e d  r i s k  f a c t o r s  f o r  D M 2  a n d
CVD, increased impaired glucose tolerance (IGT), DM2
and potentially increased CVD [18]. As obesity rates rise,
the public health significance of PCOS will increase [18].
Treatment of obesity through lifestyle intervention is a
key treatment strategy in PCOS and improves insulin
resistance, reproductive and metabolic features [19].
Diagnosis of PCOS
Until recently no universally accepted clinical definition
existed for PCOS. Over the past three decades, research
has highlighted that PCOS is a heterogeneous condition.
Symptoms and signs related to PCOS have been evalu-
ated and the initial NIH diagnostic criteria based on oli-
gomenorrhoea/amenorrhoea and clinical or biochemical
hyperandrogenism have been broadened in the 2003 Rot-
terdam or ESHRE/ASRM criteria to include PCO at
ultrasound in the key diagnostic criteria [20]. A total of
25% of young women have PCO on ultrasound and the
inclusion of PCO in diagnostic criteria has increased the
prevalence of PCOS. Recent data indicates that the preva-
lence of PCOS may be doubled on use of the ESHRE/
ASRM criteria with a prevalence of 12% (not imputing
presence of polycystic ovaries) to 18% (imputing presence
of polycystic ovaries) reported in a community sample
[5]. In 2006 the Androgen Excess PCOS Society sug-
gested further modification of the diagnostic criteria to
exclude those without symptoms (PCO on ultrasound
and oligomenorrhoea/amenorrhoea but no hyperandro-
genism) (Table 1) [21]. It should be noted that PCOS is a
diagnosis of exclusion and conditions including thyroid
Figure 1 Schema of aetiology and clinical features including re-
productive, metabolic and psychosocial features of polycystic 
ovary syndrome (PCOS). Reproduced with permission from [82].Teede et al. BMC Medicine 2010, 8:41
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dysfunction and hyperprolactinaemia should be excluded
biochemically, whilst more rare conditions should be
excluded clinically (Cushing's syndrome, virilising
tumours, and so on). However, cardiometabolic features
and insulin resistance are not currently part of the PCOS
diagnostic criteria. This is in part attributable to the lack
of accurate methods to measure insulin resistance with
measurement not currently recommended in clinical
practice [22].
With the four key diagnostic features, (oligomenor-
rhoea/amenorrhoea, clinical or biochemical hyperandro-
genism and PCO on ultrasound) there are many potential
phenotypes (Table 1) [21]. This heterogeneity of the con-
dition is further exacerbated by degree of obesity, insulin
resistance, ethnicity and other factors [21]. Both the het-
erogeneity of PCOS and the lack of an understanding of
its aetiology contribute to the evolving diagnostic criteria
and ongoing controversy. Currently the ESHRE/ASRM or
Rotterdam criteria are the agreed international diagnostic
criteria for PCOS, although further research is needed.
Clinical features of PCOS
Women with PCOS may therefore present with a variety
of serious clinical sequalae including psychological prob-
lems (reduced quality of life, poor self-esteem, depres-
sion, anxiety) [23,24], reproductive manifestations
(hirsutism, infertility and pregnancy complications) [25],
and metabolic implications (insulin resistance, metabolic
syndrome, IGT, DM2 and potentially CVD) [14,26,27]
(Figure 1 and Appendix 1). Given the heterogeneous
nature of PCOS (Table 1) and the spectrum of clinical
features, presentation can vary across the life cycle. PCOS
is a chronic condition with psychological and reproduc-
tive manifestations usually beginning in adolescence then
transitioning to include infertility and increasing meta-
bolic complications over time. However, when combined
with obesity, metabolic implications of PCOS such as
IGT, DM2 and the metabolic syndrome can present in
adolescence [28,29].
Reproductive features of PCOS
Ovarian dysfunction and infertility
Ovarian dysfunction usually manifests as oligomenor-
rhoea/amenorrhoea resulting from chronic oligo-ovula-
tion/anovulation [30]. However, prolonged anovulation
can lead to dysfunctional uterine bleeding which may
mimic more regular menstrual cycles. The majority of
PCOS patients have ovarian dysfunction, with 70% to
80% of women with PCOS presenting with oligomenor-
rhoea or amenorrhoea. Among those with oligomenor-
r hoea,  80% t o 90% will  be  dia gnosed wit h PCOS  [ 3 0].
Among those with amenorrhoea, only 40% will be diag-
nosed with PCOS as hypothalamic dysfunction is a more
common cause [31]. Oligomenorrhoea occurs usually in
adolescence, with onset later in life often associated with
weight gain. Menstrual irregularity is then often masked
by the oral contraceptive pill (OCP), until cessation, when
the underlying irregular cycles recur. Menorrhagia can
occur with unopposed oestrogen and endometrial hyper-
plasia, further exacerbated by elevated oestrogen levels in
obesity. Whilst inadequate research exists, it is generally
recommended that greater than four cycles per year may
protect the endometrium. Women with regular men-
strual cycles can also now be diagnosed with PCOS based
on newer diagnostic criteria (Table 1) [21].
PCOS is the most common cause of anovulatory infer-
tility. It accounts for 90% to 95% of women attending
infertility clinics with anovulation. However 60% of
women with PCOS are fertile (defined as the ability to
conceive within 12 months), although time to conceive is
often increased [30]. In those with PCOS and infertility,
90% are overweight. Obesity independently exacerbates
infertility, reduces efficacy of infertility treatment and
induces a greater risk of miscarriage [30]. There is cur-
rently an active debate about the appropriate limit for
body mass index for assisted reproduction therapies,
given the reduced success rates and the demonstrated
risks of pregnancy in overweight women [32]. Ideally,
weight should be optimised prior to pregnancy. Age-
Table 1: The different diagnostic criteria for polycystic ovary syndrome (PCOS)
National Institutes of Health criteria 
consensus statement [83]
European Society for Human Reproduction 
and Embryology/American Society for 
Reproductive Medicine consensus 
statement [20]
Androgen Excess Society position 
statement [21]
Oligo-ovulation and clinical and/or 
biochemical signs of hyperandrogenism, and 
exclusion of other aetiologies*
Two out of three of: oligo-ovulation and/or 
anovulation, clinical and/or biochemical signs 
of hyperandrogenism, or polycystic ovaries, 
and exclusion of other aetiologies*
Hyperandrogenism (hirsutism and/or 
hyperandrogeniaemia), ovarian dysfunction 
(oligoanovulation and/or polycystic ovaries), 
and exclusion of other androgen excess 
related disorders*
Table adapted from [14], with permission of Oxford University Press, Oxford, UK.
*Congenital adrenal hyperplasia, androgen-secreting tumours, Cushing's syndrome, 21-hydroxylase-deficient non-classic adrenal hyperplasia, 
androgenic/anabolic drug use or abuse, syndromes of severe insulin resistance, thyroid dysfunction, hyperprolactinaemia.Teede et al. BMC Medicine 2010, 8:41
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related infertility also exacerbates infertility and timely
planning of families may warrant discussion.
Hyperandrogenism
The clinical and/or biochemical signs of androgen excess
in PCOS result from increased synthesis and release of
ovarian androgens. Elevated luteinising hormone and
insulin synergistically increase androgen production.
Insulin resistance leads to hyperinsulinaemia, reduces
SHBG and raises free circulating testosterone and
together, hyperandrogenism and hyperinsulinaemia
impairs ovarian follicle development. Clinical hyperan-
drogenism primarily includes hirsutism, acne and male
pattern alopecia [21]. Hirsutism is defined in females as
m a l e  t y p e  t e r m i n a l  h a i r  g r o w t h  a n d  d i s t r i b u t i o n  [ 3 3 ] .
PCOS is a common cause of hirsutism occurring in
approximately 60% of cases, however this varies with race
and degree of obesity [21]. Hirsutism should be assessed
with a standardised scoring system (Ferriman-Gallwey
score). Acne affects one third of cases and is not particu-
larly specific for PCOS [33]. Male pattern hair loss
( a n d r o g e n i c  a l o p e c i a )  i s  l e s s  f r e q u e n t l y  s e e n  i n  P C O S
cases, as it generally requires a familial predisposition.
Other features of hyperandrogenism include virilisation,
which, especially if presenting with clitoromegaly and
rapid onset, requires exclusion of other causes including
adrenal or ovarian androgen-secreting tumours.
Biochemical hyperandrogenism is present in most
patients with PCOS. Measurement of biochemical andro-
gens in PCOS is limited by poor accuracy and reproduc-
ibility of assays, which are designed for significantly
higher male androgen levels. Free androgen index mea-
surements are generally recommended, derived in the lab
from SHBG and total testosterone measurements [33].
Dehydroepiandrosterone sulfate (DHEAS) and andros-
tenedione are not routinely recommended in PCOS [21].
Metabolic features of PCOS
Dyslipidaemia
Dyslipidaemia is common in PCOS compared to weight
matched controls [34-37], with higher triglycerides and
lower high density lipoprotein cholesterol [35]. The dys-
lipidaemia occurs independent of body mass index (BMI)
[35,38] , however there is a synergistic deleterious effect
of obesity and insulin resistance in PCOS analogous to
that seen in DM2. The causes of dyslipidaemia in PCOS
are again multifactorial. Insulin resistance appears to
h a v e  a  p i v o t a l  r o l e  m e d i a t e d  i n  p a rt  b y  s t i m u l a t i o n  o f
lipolysis and altered expression of lipoprotein lipase and
hepatic lipase [35].
Insulin resistance and abnormal glucose metabolism
Insulin resistance occurs in around 50% to 80% of women
with PCOS [12], primarily in the more severe NIH diag-
nosed PCOS and in those who are overweight. Lean
women [13] and milder Rotterdam diagnosed PCOS [14]
appear to have less severe insulin resistance. A full dis-
cussion of the complex mechanisms involved in insulin
resistance, hyperinsulinaemia, DM2 and CVD is beyond
the scope of this review. Mechanisms involved in insulin
resistance are likely to be complex with genetic and envi-
ronmental contributors. Specific abnormalities of insulin
metabolism identified in PCOS include reductions in
secretion [39,40], reduced hepatic extraction [40],
impaired suppression of hepatic gluconeogenesis [41]
and abnormalities in insulin receptor signalling [42].
Interestingly, there is a paradoxical expression of insulin
resistance in PCOS whereby insulin-stimulated androgen
production persists while its role in glucose metabolism
is impaired [42]. Therefore, insulin resistance in PCOS
results in hyperinsulinaemia with its associated diverse
and complex effects on regulating lipid metabolism, pro-
tein synthesis and modulation of androgen production.
The cause of insulin resistance is likewise complex and
multifactorial with genetic and environmental contribu-
tors [15]. Lean women with PCOS often but not always
[13] have abnormalities of insulin secretion and action
compared to weight-matched control subjects [41].
Where a woman with PCOS is overweight, she may also
demonstrate extrinsic insulin resistance associated with
adiposity, which is potentially mechanistically distinct
from the insulin resistance present in lean women with
PCOS. In women with insulin resistance and PCOS, only
a subgroup develop coexistent pancreatic insufficiency
with β cell failure and go on to DM2. In this setting, insu-
lin output cannot overcome resistance and hyperglycae-
mia develops. Women with PCOS are at increased risk of
developing IGT and DM2 with prevalence rates of 31.3%
and 7.5%, respectively, compared to 14% for IGT and 0%
for DM2 in age-matched and weight-matched non-PCOS
control women [27].
Women with PCOS also develop abnormal glucose
metabolism at a younger age and may demonstrate a
more rapid conversion from IGT to DM2 [43]. The rate of
conversion from IGT to DM2 in a general Australian
population was estimated in the large cohort Australian
Diabetes, Obesity and Lifestyle (AusDiab) study at 2.9%
per year for young females [44]. Another Australian study
has reported a substantially higher conversion rate (8.7%
per year over 6.2 years) in women with PCOS [45], how-
ever this has not been uniformly reported [46]. Women
with PCOS also have higher gestational diabetes (GDM)
risk, with a recent meta-analysis reporting an odds ratio
(OR) of 2.94 [25]. The risk of GDM occurs both indepen-
dent of and is exacerbated by obesity [27,47]. Whilst there
are few adequately powered studies assessing natural his-
tory of IGT, DM2 and CVD in PCOS and there is a need
for further research, the International Diabetes Federa-Teede et al. BMC Medicine 2010, 8:41
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tion has identified PCOS as a significant non-modifiable
risk factor associated with DM2 [48].
It is increasingly clear that IGT is also a clinically rele-
vant state where early identification and intervention
improve long-term outcomes [49]. IGT has been found to
increase the risk of CVD, mortality and progression to
DM2 in general populations [44]. Recent population-
based data noted a mortality rate of 5.5% over 5 years for
those with IGT versus 1.9% with normal glucose toler-
ance [44]. Furthermore, lifestyle intervention, metformin
and glitazones can prevent IGT progression to DM2 [49],
strengthening the argument for early detection of IGT,
including in high-risk PCOS women
There are currently no generic guidelines for IGT
screening, only for DM2 based on fasting glucose or more
recently on HbA1c as a first line. However, impaired fast-
ing glucose is a poor predictor of IGT in women in gen-
eral [50] and in PCOS [27,43]. Hence the ESHRE/ASRM-
sponsored PCOS Consensus Workshop Group recom-
mend an oral glucose tolerance test in all overweight
women with PCOS [51]. Furthermore, emerging data
shows increased risk of metabolic complications in first-
degree family members of women with PCOS [52-56].
Screening for metabolic conditions may be also war-
ranted in relatives of women with PCOS, although this
requires further research.
Cardiovascular disease risk
Alongside insulin resistance, metabolic syndrome, IGT
and DM2, women with PCOS also have increased novel
cardiovascular risk factors (inflammation, oxidative stress
and impaired fibrinolysis) [14]. Also, increased early clin-
ical and subclinical markers of atherosclerosis seen in
PCOS (endothelial dysfunction, impaired pulse wave
velocity, increased carotid intima media wall thickness,
presence of carotid plaque and increased coronary artery
calcification) [34,57] are further exacerbated by obesity
[27,58,59]. Given that large longitudinal cohort studies
have reported up to 65% of CVD deaths occur in subjects
with impaired glucose metabolism [60] and that IGT and
DM2 are increased in PCOS, it would be expected that
women with PCOS would have increased CVD risk.
There is currently a lack of long-term studies in PCOS to
appropriately address CVD risk. Some studies support an
increased risk of CVD in PCOS [18], but these findings
are not universal [61] and further research is needed. A
recent study in postmenopausal women with premeno-
p a u s a l  f e a t u r e s  o f  P C O S  n o t e d  h i g h e r  p r e v a l e n c e  o f
angiographic coronary artery disease and that PCOS was
associated with worsened cardiovascular event-free sur-
vival [18].
Psychological features of PCOS
Most research has focused on the biological and physio-
logical aspects of the syndrome. The challenges to femi-
nine identity and body image due to obesity, acne and
excess hair, as well infertility and long-term health-
related concerns compromise quality of life and adversely
impact on mood and psychological well-being [23,62].
Limited studies to date have reported that women who
have PCOS are more prone to depression, anxiety, low
self-esteem, negative body image, and psychosexual dys-
function [63,64]. The other critical aspect of psychosocial
impact in PCOS is the negative impact of mood distur-
bance, poor self-esteem and reduced psychological well-
being on motivation and on ability to implement and sus-
tain successful lifestyle changes that are critical in this
condition [19]. These issues all need to be explored and
addressed as part of PCOS assessment and management.
Investigations and assessment in PCOS
There is no single diagnostic test for PCOS. Key investi-
gations include prolactin and thyroid stimulating hor-
mone to exclude other disorders and testosterone, SHBG
and free androgen index to assess androgen status [33].
Other investigations include a pelvic ultrasound for ovar-
ian morphology and endometrial thickness. An oral glu-
cose tolerance test (rather than fasting glucose) and lipid
profiles are appropriate in all women at diagnosis and 1 to
2 yearly after this, where women are overweight or have
an increased risk of DM2 (for example, family history of
DM2 in first-degree relatives, increased age or high-risk
ethnic group). As noted, insulin levels should not be mea-
sured in clinical practice because of assay variability and
inaccuracy. Metabolic syndrome and abnormal glucose
metabolism best reflect insulin resistance in this popula-
tion.
Treatment of PCOS
Targeted approach to therapy
Treatment options need to be tailored to the clinical pre-
sentation. Education on short-term and long-term sequa-
lae of PCOS from a reliable independent source is
important in allaying anxiety and minimising the impact
of illness in chronic disease (Table 2). As a prelude to
treatment psychological features need to be acknowl-
edged, discussed and counselling considered [65], to
enable lifestyle change which is unlikely to be successful
without first addressing education and psychosocial
issues (Figure 2 and Appendix 2).
Weight loss, exercise and lifestyle interventions
Lifestyle change is first line treatment in an evidence-
based approach in the management of the majority of
PCOS women who are overweight [19]. Furthermore,
prevention of excess weight gain should be emphasised in
all women with PCOS of both normal or increased body
weight. As little as 5% to 10% weight loss has significant
clinical benefits improving psychological outcomes [66],
reproductive features (menstrual cyclicity, ovulation andTeede et al. BMC Medicine 2010, 8:41
http://www.biomedcentral.com/1741-7015/8/41
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fertility) [9,67] and metabolic features (insulin resistance
and risk factors for CVD and DM2). Evidence shows that
lifestyle change with small achievable goals results in clin-
ical benefits even when women remain in the overweight
or obese range, [9,68,69]. Standard dietary management
of obesity and related comorbidities [70] is a nutritionally
adequate, low fat (approximately 30% of energy, saturated
fat approximately 10%), moderate protein (approximately
15%) and high carbohydrate intake (approximately 55%),
with increased fibre-rich wholegrain breads, cereals,
fruits and vegetables and moderate regular exercise. A
moderate energy reduction diet (500 to 1,000 kcal/day
reduction) reduces body weight by 7% to 10% over a
period of 6 to 12 months. Simple and practical tips that
can be covered in minutes in medical consultation
include targeting fruit juice, soft drinks, portion sizes and
high-fat foods. Incorporating simple moderate physical
activity including structured exercise (at least 30 min/
day) and incidental exercise increases weight loss and
improves clinical outcomes in PCOS, compared to diet
alone [71]. Exercise alone also improves clinical out-
comes. As in the general population, goals for exercise
must focus on overall health benefits not weight loss per
se.
Fad diets are not encouraged as short-term weight loss,
if achieved, is rarely sustainable [72]. The advantages of
specific dietary approaches over that of caloric restriction
alone are still unclear and more research is needed. Pro-
posed specific dietary approaches in PCOS include high
protein, low carbohydrate and low glycaemic index/gly-
caemic load diets. A number of small studies assessing
specific dietary approaches in PCOS show similar results
for diets moderately increased in dietary protein or car-
bohydrate [73-75] with one study reporting greater
weight loss where a high protein supplement was added
to a standard energy reduced diet [76]. Two small studies
have assessed very low carbohydrate diets in PCOS, and
one study reported on an audit of reduced glycaemic load
diets in clinical practice. While reductions in weight,
BMI, waist circumference, fasting insulin or testosterone
were reported, these studies lacked a control group [77-
79]. The current evidence suggests that a range of dietary
strategies, as long as they are safe, nutritionally adequate
and sustainable in the long term, will similarly improve
weight, and reproductive and metabolic features in PCOS
[19].
Pharmacological therapy in PCOS
There is currently no ideal medical PCOS therapy that
fully reverses underlying hormonal disturbances and
treats all clinical features. The OCP does improve hyper-
androgenism and insulin sensitisers (primarily Met-
formin) reduce insulin resistance in PCOS [80].
Generally, medical therapy is targeted to symptoms and
should not be used as an alternative to lifestyle therapy in
PCOS (Figure 2). Simple medical therapy is summarised
in Appendix 2. The OCP has long been used in PCOS to
induce regular cycles, protect the endometrium and treat
hyperandrogenism. Mechanisms of action include a sig-
nificant first pass hepatic effect, increasing production of
hepatic proteins including sex hormone binding globulin.
This reduces free circulating androgen levels, even with
low dose OCPs. This important mechanism of antiandro-
genic action does not occur with progestin alone or non-
oral oestrogen containing contraceptive preparations.
The OCP also reduces ovarian androgen production.
There has been concerning data that the OCP can
increase insulin resistance and worsen glucose tolerance.
Studies are inadequate and data conflicting with more
research needed, however consideration should be given
to cardiometabolic effects of medical therapy and low
Table 2: Evidence-based government funded resources to 
inform consumers and/or health professionals in 
polycystic ovary syndrome (PCOS)
Resource Description
http://
www.managingpcos.org.au
Evidence-based independent 
consumer and health 
professional information
http://www.jeanhailes.org.au Evidence-based independent 
consumer and health 
professional information
PCOS patient fact sheets Freely available: link from 
website above
Figure 2 Summary of a targeted approach to therapy in polycys-
tic ovary syndrome (PCOS). Reproduced with permission from [82].Teede et al. BMC Medicine 2010, 8:41
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Page 7 of 10
dose OCP preparations may be a preferable alternative,
with similar efficacy and reduced cardiometabolic effects
[80].
Metformin has had an increasing role in PCOS man-
agement [22,81], improving clinical features (ovulation,
cycle regulation, and potentially hirsutism) with positive
cardiometabolic effects [22,81]. It does not appear to
induce weight loss, although based on studies in DM2 it
may assist in preventing future weight gain. Based on
International Diabetes Federation recommendations
[48,80], metformin has a role in prevention of diabetes
where lifestyle therapy is inadequate. Given the increased
insulin resistance and high risk of DM2, this includes
PCOS especially if other risk factors including excess
weight, family history of DM2, metabolic syndrome or
prediabetes exist [22]. In infertility, the role of metformin
remains controversial. It does reduce hyperstimulation in
those on other fertility therapies, however more research
here is important. When using metformin it is better tol-
erated if started at 500 mg of slow release daily and
increased over weeks to months to reach 2 g daily. Lactic
acidosis is a rare side effect in those with other significant
illnesses including renal impairment [22]. It is important
to note that neither metformin nor the OCP are approved
by most regulatory authorities specifically for PCOS. The
OCP is indicated for contraception and metformin for
the treatment of diabetes. However, both treatments are
recommended by international and national endocrine
societies and are evidence based [20]. A detailed discus-
sion of infertility therapy is beyond the scope of this
review, however clomiphene is generally used as initial
medical therapy.
Conclusions
PCOS is a common complex condition in women associ-
ated with psychological, reproductive and metabolic fea-
tures. It is a chronic disease with manifestations across
the lifespan and represents a major health and economic
burden. Both hyperandrogenism and insulin resistance
contribute to pathophysiology of PCOS. Insulin resis-
tance occurs in the majority of women with PCOS, espe-
cially those who are overweight, and these women have a
high risk of metabolic syndrome, prediabetes and DM2.
Management should focus on support, education,
addressing psychological factors and strongly emphasis-
ing healthy lifestyle with targeted medical therapy as
required. Treatment for the large majority is lifestyle
focused and an aggressive lifestyle-based multidisci-
plinary approach is optimal in most cases to manage the
features of PCOS and prevent long-term complications.
Small achievable goals of 5% loss of body weight result in
significant clinical improvement even if women remain
clinically in the unhealthy overweight or obese range.
Addressing hyperandrogenism is clinically important and
monitoring for and managing longer-term metabolic
complications, including dyslipidaemia, IGT, DM2, and
cardiovascular risk factors, is crucial. Consideration
should be given to screening high-risk family members
for metabolic abnormalities also. Overall, further
research is needed in this complex condition. In the
interim, comprehensive evidence-based guidelines are
needed to guide consumers and clinicians in optimal
PCOS management.
Appendix 1
Reproductive, metabolic and psychosocial features of 
polycystic ovary syndrome (PCOS)
Clinical features of PCOS
(1) Reproductive features: hyperandrogenism, hirsutism,
ovulatory and menstrual dysfunction, infertility, compli-
cations in pregnancy, miscarriage, pregnancy-induced
diabetes (gestational diabetes), pregnancy-induced
hypertensive disorders and neonatal complications and
increased endometrial hyperplasia.
(2) Metabolic features: insulin resistance, metabolic
syndrome, dyslipidaemia, high rates of premature
impaired glucose tolerance, type 2 diabetes and increased
cardiovascular risk factors.
(3) Psychological features: anxiety, depression, poor
self-esteem, reduced quality of life, negative body image.
Appendix 2
Summary of treatment options in polycystic ovary 
syndrome (PCOS)
Oligomenorrhoea/amenorrhoea
• Lifestyle change (5% to 10% weight loss and struc-
tured exercise).
• Oral contraceptive pill (OCP; low oestrogen doses, 
for example 20 μg may be preferable).
• Cyclic progestins (for example, 10 mg medroxypro-
gesterone acetate for 14 days every 2 to 3 months).
• Metformin (improves ovulation and menstrual 
cyclicity).
Hirsutism treatment recommendations
• Cosmetic therapy.
• Laser treatment.
• Eflornithine cream can be added and may induce a 
more rapid response.
Pharmacological therapy
• Medical therapy if patient concerned about hirsut-
ism and cosmetic therapy ineffective, inaccessible or 
unaffordable.
• Primary therapy is the OCP (monitor glucose toler-
ance in those at risk of diabetes).
• Antiandrogen monotherapy should not be used 
without adequate contraception.
• Trial therapies for ≥ 6 months before changing dose 
or medication.Teede et al. BMC Medicine 2010, 8:41
http://www.biomedcentral.com/1741-7015/8/41
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• Combination therapy: if ≥ 6 months of OCP is inef-
fective, add antiandrogen to OCP (daily spironolac-
tone 50 mg twice a day or cyproterone acetate 25 mg/
day for days 1 to 10 of the active OCP tablets).
Infertility
• Obesity independently exacerbates infertility and 
reduces effectiveness of interventions. Maternal and 
foetal pregnancy risks are greater and long-term met-
abolic outcomes in the child are related to maternal 
weight at conception. Consistent with international 
guidelines, women who are overweight prior to con-
ception should be advised on folate, smoking cessa-
tion, weight loss and optimal exercise, prior to 
additional interventions.
• Given age-related infertility, advise women to opti-
mise family planning.
• Infertility therapies may include clomiphene, gonad-
otrophins and in vitro fertilisation.
Metabolic syndrome, prediabetes, diabetes and 
cardiovascular disease risk
Obesity independently causes metabolic complications;
lifestyle/exercise is critical:
• Lifestyle change with a 5% weight loss reduces dia-
betes risk by approximately 50% to 60% in high-risk 
groups [49].
• Metformin* reduces the risk of diabetes by approxi-
mately 50% in high-risk groups [49].
*Metformin and the OCP are not currently approved
for use to manage PCOS by many regulatory bodies. The
OCP is primarily indicated for contraception and met-
formin for diabetes. However, their use is recommended
by international and national specialist societies and is
evidence based [22].
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